2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 769

Evaluation of Soluble Alpha-Klotho in Neuropsychiatric Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 562

Evaluation of T Helper Cell 1(Th1) – and T Helper Cell 17(Th17) – Associated Chemokines As Prognostic Biomarkers for Tumor Necrosis Factor (TNF) Inhibitor Therapy in Rheumatoid Arthritis (RA)

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 670

Evaluation of the Predictive Value of Non-Specific Musculoskeletal Symptoms in Preclinical Phases of Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 883

Evaluation of Thiopurine Metabolites Monitoring in Patients Treated with Azathioprine for Rheumatic Diseases

Vasculitis Poster I

9:00AM-11:00AM: Abstract Number: 289

Evaluation of Usefulness of Krebs Von Den Lungen-6 As a Biomarker of Interstitial Lung Disease with Polymyositis and Dermatomyositis Including in the Short Time Course after Treatment

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 194

Events Upstream of Caspase-1 Activation in NLRP3-Mediated Cell Death in NOMID

Innate Immunity and Rheumatic Disease Poster I

9:00AM-11:00AM: Abstract Number: 124

Experiences with a Structured Questionnaire for Administrative Personnel to Discriminate Urgent and Non-Urgent Rheumatic Patients Referred from Primary to Secondary Care

Health Services Research Poster I: Diagnosis, Management and Treatment Strategies

9:00AM-11:00AM: Abstract Number: 142

Exploration of General Practioners’ Difficulties with Methotrexate and Anti-TNF Therapies in Routine Practice

Health Services Research Poster I: Diagnosis, Management and Treatment Strategies

9:00AM-11:00AM: Abstract Number: 78

Exploratory Analysis of Somatic Symptoms in Fibromyalgia By Multidimensional Scaling and Latent Class Analysis

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster I

9:00AM-11:00AM: Abstract Number: 837

Exposure to ACE Inhibitors Prior to Onset of Scleroderma Renal Crisis Is Not Associated with Increased Risk of Mortality in a Large Retrospective Cohort Study

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 590

Expression Levels of Selected Genes May Predict Response to TNF Alpha Blockers or Rituximab in the Individual Rheumatoid Arthritis Patient

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 22

Expression of High Mobility Group Box 1 Protein and the Receptor for Advanced Glycation End Products in Primary Gouty Arthritis

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

9:00AM-11:00AM: Abstract Number: 813

Expression of Inducible Costimulator Ligand (ICOSL) on CD4+ T Cells in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 880

Extra-Corporeal Membrane Oxygenation and Diffuse Alveolar Haemorrhage: A Single Centre Case Series and Analysis of the ELSO Database

Vasculitis Poster I

9:00AM-11:00AM: Abstract Number: 712

Factors Associated with Anti-TNF Treatment in a Longitudinally Followed Ankylosing Spondylitis (AS) Cohort

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].